Upstate Active Clinical Trials Seeking Participants
Study title
A randomized, parallel group trial evaluating safety and efficacy of BIOD-123 compared to insulin lispro (Humalog?) in subjects with type 1 diabetes using basal-bolus insulin injection therapy
IRB number
374927
What is the purpose of the study?
The study is being done to evaluate how safe and effective the study drug, BIOD-123 is when compared to Humalog
Who is eligible?
Participants must be 18 or older with established clinical diagnosis of type 1 diabetes for more than 1 year, using basal-bolus insulin injection therapy for at least the past 6 months.
What is involved if I participate?
- How long is the study?
approximately 5 months - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Participants will come to 12 study visits at the Clinical Research Unit, and participate in telephone visits in between clinic visits. Procedures during study visits include: physical exams, blood collection, urinalysis, ECG, liquid meal challenge test (1 visit). Subjects will wear a continuous glucose monitoring device, as well as keep a diary of blood glucose readings throughout the study
Who is the doctor administering the study?
Ruth Weinstock, MD, PhD
Where will the study take place?
Clinical Research Unit, IHP
Who can I contact for more information?
- Name: Suzan Bristol
- Phone: 315-464-9006
- Email: carusons@upstate.edu
- Fax: 315-464-9076
Other information:
Study insulins will be provided for the length of the study, along with a glucose meter and testing supplies.
If you are interested in this trial, please contact the study coordinator or investigator noted above.
